Early Prostate Cancer Articles & Analysis
11 news found
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate ...
ByBayer AG
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) ...
The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells leverages its proprietary ISET® Circulating Tumor Cells (CTC) platform, combined with cutting-edge downstream analyses, to generate a novel and powerful approach to ...
Compared to standard systematic biopsies, MRI-targeted fusion biopsies improve the detection of clinically significant prostate cancer. Studies have shown MRI can be a cost-effective and accurate first-line diagnostic tool for the early detection of prostate cancer. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
Prostate cancer is the second most common and lethal cancer among men in the United States. ...
Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that Eric Klein, MD, Chairman of the Glickman Urological & Kidney Institute at Cleveland Clinic, delivered two presentations at the annual meeting of the American Urological Association regarding ...
Puerto Rico has one of the highest rates of prostate cancer in the world and this is the leading cause of death (17%) related to cancer in men. "The high incidence of mortality among Puerto Rican men due to prostate cancer on the island is of great concern to all of us. It is time to take concrete action and ...
TORONTO, CANADA -- (March 23, 2021) Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announces $5.1M in financing provided by BDC Capital, through the Bridge Financing Program, and Export Development Canada (EDC). ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. ...
“The traditional approach to early detection strategies for prostate cancer based on standard serum PSA testing is limited by relatively poor diagnostic accuracy and predictive value. ...